VC-backed Rhythm files for IPO

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

Cerecor closes first tranche of $32 mln Series B

Cerecor has closed on the initial tranche of a $32 million Series B funding. New Enterprise Associates, Apple Tree Partners and MPM Capital led the round. Based in Baltimore, Cerecor is a biopharmaceutical firm focused on developing treatments for patients suffering from nervous system disorders.

True North Therapeutics bags $22 mln Series A

South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures.

Proteon Therapeutics grabs $45 mln Series D

Proteon Therapeutics said Friday that it has raised $45 million in Series D financing. Abingworth led the round with participation from Deerfield Management Company, Pharmstandard International S.A., TVM Capital, Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners and the Vectis Healthcare and Life Sciences Fund. In addition to the funding, Tim Haines, a partner at Abingworth, and Dmitry Kobyzev, an investment manager at Inbio Ventures, have been added to Proteon Therapeutics’ board of directors. Headquartered in Waltham, Mass., Proteon Therapeutics is a biopharmaceutical firm focused on treating kidney and vascular diseases.

Iconic Therapeutics snags $20 mln

Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.

VC-backed Syndax Pharmaceuticals files for IPO

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.


VC-backed TriVascular files for IPO

TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.

MPM Capital Takes Minority Stake in InformedDNA

MPM Capital has acquired a minority stake in InformedDNA, a US provider of genetic counseling and genetic benefits management services. The investment fr­om MPM’s SunStates Fund will be used to expand InformedDNA’s current genetic benefits utilization management offerings while also funding the development of new specialty genetic services for the pharmaceutical industry.

Epizyme Files for an IPO

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

23andMe Raises More Than $50M From Milner, NEA, Brin, Google, Others

23andMe, Inc. said it raised more than $50 million in a Series D financing with new investor Yuri Milner joined by existing investors Google co-founder Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. The company said the Series D investment, along with rapidly decreasing costs, allowed it to lower the price of its Personal Genome Service to $99,

Selexys Pharmaceuticals Completes Series A Led by MPM Capital

Selexys Pharmaceuticals has completed a $23 million Series A equity financing, led by MPM Capital. Selexys has also entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

Astute Medical Wraps Up Big Biomarker Round

Astute Medical, the San Diego-based biomarker-based medical diagnostics firm, took in more than $40 million in a big Series C round, the company revealed. The financing was led by MPM Capital, and included new investor Kaiser Permanente Ventures. Prior backers De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation also joined […]

Aratana Therapeutics Inks $15M

Aratana Therapeutics, a company developing medicines for companion animals, has closed on $15 million in Series B financing. The company, since its launch earlier this year, has raised a total of $31 million. Existing shareholders MPM Capital, Avalon Ventures and Cultivian Ventures contributed to the round, as did new investor the Ewing Marion Kauffman Foundation. The company is based in Kansas City, Kansas.

Young Verastem Files for an IPO

Verastem, a Cambridge, Mass.-based biopharmaceutical company focused on developing cancer-fighting drugs, has filed a registration statement with the SEC to go public. The number of shares and price range have not yet been determined. The 15-month-old company has raised $48 million in venture financing since its founding, including from Advanced Technology Ventures, MPM Capital, Bessemer […]

Valeritas Lands $150M Series C

Valeritas Inc., a Bridgewater, N.J.-based developer of drug delivery systems for the diabetes market, has raised $150 million in Series C financing. The funding will support commercialization of its V-Go disposable insulin delivery device. Welsh, Carson, Anderson & Stowe led the financing and assumes a controlling interest in Valeritas. Previous investors MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, ONSET Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures also participated.

Theraclone Sciences Adds $10.6M to Series B

Theraclone Sciences Inc. has added $10.6 million to its Series B round, closing the financing with a total of $41 million. ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the financing. The money will be used to continue clinical and discovery programs.

Nevro Inks $58M For Chronic Pain Treatment

Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget